Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00645177 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer
A Phase 2 study, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT00645177 is a Phase 2 study that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 10 participants.
The verdict
NCT00645177, a Phase 2 study, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effect of ABT-869 plus paclitaxel compared to paclitaxel alone on disease progression in metastatic breast cancer.
Interventions
- DRUG paclitaxel
- DRUG ABT-869
- DRUG Placebo for ABT-869
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2008-07 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00645177
The ClinicalTrials.gov registry entry for NCT00645177 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which paclitaxel is the first listed.
NCT00645177 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00645177 about?
NCT00645177 is a clinical study titled "Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer". The purpose of this study is to determine the effect of ABT-869 plus paclitaxel compared to paclitaxel alone on disease progression in metastatic breast cancer.
What is the current status of trial NCT00645177?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2008-07. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00645177?
The interventions under investigation include: paclitaxel (DRUG), ABT-869 (DRUG), Placebo for ABT-869 (DRUG).
Who is sponsoring clinical trial NCT00645177?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.